flucytosine has been researched along with cytarabine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentrude, WG; Beres, J; Kruppa, G; McKernan, PA; Robins, RK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cangir, A; Rivera, R | 1 |
| Burchenal, JH; Currie, VE; Dowling, MD; Fox, JJ; Krakoff, IH | 1 |
| Kreis, W | 1 |
| Fox, JJ; Otter, BA | 1 |
| Gorree, GC; Herscheid, JD; Hoekstra, A; Moonen, P; Visser, GW; Zwaagstra, O | 1 |
| Wingfield, HJ | 1 |
| Bacher, J; O'Leary, T; Pizzo, PA; Thaler, M | 1 |
| Ganeshaguru, K; Hoffbrand, AV; Tattersall, MH | 1 |
1 review(s) available for flucytosine and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for flucytosine and cytarabine
| Article | Year |
|---|---|
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cyclic CMP; Cytosine Nucleotides; Leukemia, Experimental; Mice; Protein Kinases | 1985 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Trichosporon sepsis and leukemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Bleomycin; Child; Cytarabine; Enterobacteriaceae Infections; Flucytosine; Humans; Leukemia, Lymphoid; Male; Mycoses; Sepsis; Vincristine; Yeasts | 1975 |
Experimental and clinical studies on nucleoside analogs as antitumor agents.
Topics: Aged; Animals; Cytarabine; Drug Resistance; Flucytosine; Fluorouracil; Humans; Leukemia L1210; Leukemia, Experimental; Male; Methotrexate; Mice; Nasopharyngeal Neoplasms; Structure-Activity Relationship | 1975 |
Physiological distribution of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine (AAFC) in man.
Topics: Administration, Oral; Cytarabine; Flucytosine; Humans; Injections, Intravenous; Intestinal Absorption; Time Factors | 1975 |
Nucleosides. XCI. Some chemical properties of the antileukemic agent 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine.
Topics: Animals; Antineoplastic Agents; Biological Assay; Chemical Phenomena; Chemistry; Cytarabine; Flucytosine; Hydrolysis; Kinetics; Male; Rats; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Uracil | 1975 |
Synthesis and tumour-localizing properties of [18F]-5-fluorocytosine-arabinoside and [18F]-5-fluorocyclocytidine.
Topics: Ancitabine; Animals; Cricetinae; Cytarabine; Flucytosine; Fluorine; Melanoma, Experimental; Mesocricetus; Radioisotopes; Radionuclide Imaging; Tissue Distribution | 1986 |
Absence of fungistatic antagonism between flucytosine and cytarabine in vitro and in vivo.
Topics: Candida; Cryptococcus neoformans; Cytarabine; Cytosine; Female; Flucytosine; Humans; Microbial Sensitivity Tests; Middle Aged | 1987 |
Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candidiasis; Cytarabine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Flucytosine; Ketoconazole; Neutropenia; Rabbits; Rifampin | 1988 |
The mechanisms of action of three fluorine substituted cytosine analogs: implications for cancer chemotherapy.
Topics: Antineoplastic Agents; Arabinose; Cells, Cultured; Cytarabine; Cytidine; Cytosine; Deoxyuridine; DNA; Flucytosine; Fluorine; Humans; Lymphocytes; Nucleosides; Thymidine; Tritium | 1974 |